Author

Tammy McCarty

Institution: Mayo Clinic

Observed institution: Mayo Clinic

OpenAlex ID: A5035875752

Phase II Trial of Lenalidomide (Revlimid™) with Cyclophosphamide and Dexamethasone (RCd) for Newly Diagnosed Myeloma

2008 · Shaji Kumar, Suzanne Hayman, et al. · Blood · 20

Intraocular Pressure–Related Events After Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion

2021 · Ahmad A. Aref, Ingrid U. Scott, et al. · JAMA Ophthalmology · 14

Cost-Utility Comparison of Bevacizumab and Aflibercept in the Treatment of Central or Hemiretinal Vein Occlusion in the SCORE2 Trial

2023 · Steven M. Kymes, Neal L. Oden, et al. · JAMA Ophthalmology · 10

Baseline Characteristics and Outcomes After Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion

2022 · Ingrid U. Scott, Neal L. Oden, et al. · JAMA Ophthalmology · 6

The effect of distance reiki on patient reported quality of life, correlated with changes in immune repertoires among patients with multiple myeloma: A pilot study.

2024 · Tiffany Nyamao, Rahma M. Warsame, et al. · Journal of Clinical Oncology

Works count: 5

Citation count: 50

H-index: 4

I10-index: 3